CEO, Dynavax Technologies
Appears in 1 story
Leading company through $2.2B acquisition by Sanofi
Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles shot in development. The 39% premium signals desperation: Sanofi is playing catch-up in a vaccine market projected to hit $37.2 billion by 2033, driven by the largest aging population in human history. By 2050, 2.1 billion people will be over 60—triple the population over 80. The deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance and other customary regulatory approvals.[1]
Updated Feb 4
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
